Stocks Health care OKYO
NASDAQ · Health careOKYO Pharma Ltd (OKYO)
It posted a net loss of $4.7M. In fiscal 2025 capital spending exceeded operating cash flow by $1.8M. At March 31, 2025 it held $1.6M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on August 7, 2026.
Key facts about OKYO Pharma Ltd
- Net worth
- OKYO Pharma Ltd has a market value (market cap) of $43.3M at the latest share price, and shareholders' equity of -$5.5M on its balance sheet at March 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $1.8M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer, amended), 20-F/A) was filed with the SEC on August 7, 2026 and covers the period to March 31, 2026. Open on SEC EDGAR
What OKYO Pharma Ltd does
OKYO Pharma Ltd is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker OKYO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$4.7M | -$0.20 | -$1.8M |
| 2024 | n/a | -$16.8M | -$0.57 | n/a |
| 2023 | n/a | -$13.3M | -$0.61 | -$7.7M |
| 2022 | n/a | -$5.4M | -$0.36 | -$5.5M |
| 2022 | n/a | -$3.4M | -$0.32 | -$1.6M |
| 2020 | n/a | -$1.5M | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What OKYO Pharma Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026
- September 29, 2026
- September 9, 2026
- September 8, 2026
- August 7, 2026Annual report (foreign issuer, amended) 20-F/A · period to March 31, 2026
- July 28, 2026
- July 27, 2026
- July 23, 2026
- July 23, 2026
- July 22, 2026
Insider trades
What the people running OKYO Pharma Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 27, 2026 | Patil Rajkumar V.Chief Scientific Officer | Bought | 3,363 | $5K |
| July 27, 2026 | Patil Rajkumar V.Chief Scientific Officer | Received as pay | 3,363 | $5K |
| July 22, 2026 | Dempsey Robert JohnCHIEF EXECUTIVE OFFICER, Director | Bought | 15,000 | $23.1K |
| July 22, 2026 | Dempsey Robert JohnCHIEF EXECUTIVE OFFICER, Director | Received as pay | 15,000 | $23.1K |
| July 21, 2026 | Cerrone Gabriele MDirector, 10% owner | Boughtindirect | 22,500 | $32.6K |
| July 21, 2026 | Mantelli FlavioCHIEF MEDICAL OFFICER | Bought | 20,000 | $28K |
| July 21, 2026 | Jacob Gary SCHIEF DEVELOPMENT OFFICER, Director | Bought | 3,500 | $4.9K |
| July 21, 2026 | Brancaccio John PDirector | Bought | 5,000 | $7.4K |
Who owns OKYO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Chernett Jorey13G, passive | 9.5% | February 13, 2026 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 7.7% | May 15, 2026 |
| Woodline Partners LP13G, passive | 7% | May 15, 2026 |
| Laura Natalia Monica Fonda13G, passive | 5.01% | October 29, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 19 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Woodline Partners LP | 3,652,768 | +578 |
| Stonepine Capital Management, LLC | 862,996 | +12,996 |
| Maven Securities LTD | 809,317 | -366,218 |
| Balyasny Asset Management L.P. | 580,596 | -4,200 |
| Opaleye Management Inc. | 375,204 | new |
| UBS Group AG | 55,009 | -4,751 |
| XTX Topco Ltd | 37,769 | +117 |
| Choreo, LLC | 33,255 | new |
| Quantinno Capital Management LP | 33,255 | new |
| Cerity Partners LLC | 12,812 | 0 |
| Geode Capital Management, LLC | 12,090 | 0 |
| Renaissance Technologies LLC | 11,200 | new |
| Jane Street Group, LLC | 10,302 | new |
| Steward Partners Investment Advisory, LLC | 6,000 | new |
| EFG International AG | 923 | 0 |
| Osaic Holdings, Inc. | 152 | 0 |
| Continuum Advisory, LLC | 50 | new |
| Morgan Stanley | 10 | 0 |
| Caitong International Asset Management Co., Ltd | 3 | new |
Insiders
6 insiders reported holding 11,076,567 shares in total, about $14.2M at the last price.
| Holder | Shares |
|---|---|
| Cerrone Gabriele MDirector, 10% owner | 10,873,91610,873,916 held indirectly |
| Jacob Gary SCHIEF DEVELOPMENT OFFICER, Director | 112,420 |
| Brancaccio John PDirector | 35,201 |
| Patil Rajkumar V.Chief Scientific Officer | 20,030 |
| Mantelli FlavioCHIEF MEDICAL OFFICER | 20,000 |
| Dempsey Robert JohnCHIEF EXECUTIVE OFFICER, Director | 15,000 |
Questions about OKYO
What does OKYO Pharma Ltd do?
OKYO Pharma Ltd is a company in the Health care sector, listed on NASDAQ as OKYO. Its shares trade on NASDAQ under the ticker OKYO.
What is OKYO Pharma Ltd's net worth?
OKYO Pharma Ltd has a market value (market cap) of $43.3M at the latest share price, and shareholders' equity of -$5.5M on its balance sheet at March 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is OKYO Pharma Ltd profitable?
No. In fiscal 2025 it reported a net loss of $4.7M.
When did OKYO Pharma Ltd last report?
Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on August 7, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the foreign issuer update from October 6, 2026.
Similar companies
Compare OKYO with
Follow OKYO
Get an email when OKYO Pharma Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values OKYO Pharma Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.